Page 6 - Orphanet Journal News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Duchenne Muscular Dystrophy Global Market Report 2023

Major players in the duchenne muscular dystrophy market are Bristol Myers Squibb Company, FibroGen Inc., Italfarmaco SpA, NS Pharma Inc., Pfizer Inc., PTC.

New yorkUnited statesUnited kingdomSouth koreaEli lillyUniversity of texas southwesternAkashi therapeutics incAavantibio incCapricor therapeutics incNippon shinyaku co ltdHamon centerAcceleron pharma incBiomarin pharmaceutical incMuscular dystrophy global market reportAcceleron pharmaCapricor therapeutics

Rhythm Pharmaceuticals (RYTM) Announces Two Publications Detailing Burden of Hyperphagia and Obesity on Patients and Caregivers Living with Bardet-Biedl Syndrome

Rhythm Pharmaceuticals (RYTM) Announces Two Publications Detailing Burden of Hyperphagia and Obesity on Patients and Caregivers Living with Bardet-Biedl Syndrome
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomHannah deresiewiczDavid connollyAndream haqqAdam daleyDavid meekerStern investor relations incCorporate communicationsRhythm pharmaceuticals incDrug administrationUnited kingdom medicines healthcare products regulatory agencyUniversity of albertaEuropean commissionEuropean unionDepartment of pediatrics

Uncontrolled Disease Common in Patients Grappling With Myasthenia Gravis

A real-world study of 5 European countries shows frequent misdiagnoses/delays in diagnosis, acute hospitalizations, and quality-of-life impairments.

United kingdomUnited statesEuropean unionOrphanet journal

Assessing the Impact of the Orphan Drug Act 40 Years Later

The act was passed in 1983 and has contributed to increased research and development on treatments for rare diseases.

United statesDrug designation programOrphanet journalOrphan drug actOrphan drug designation programOrphan drug designation programOrphan drugOrphan drug approvalsRare disease drug development

Genomenon Wins Best of Show Award at Bio-IT World 2023 Conference and Expo

Ann Arbor, MI (PRWEB) May 30, 2023 Genomenon Inc., a genomic intelligence company, today announced that it was awarded Best of Show at Bio-IT World

United statesInozyme pharmaMike kleinLife sciencesGenomenon incShow awardsGenomic intelligenceGenomic language processingOrphanet journalRare diseasesRare disease prevalencePress release